Last update 23 May 2026

SHR-9839

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
SHR 9839, SHR-9839, SHR9839
Target
EGFR x c-Met
Action
antagonists, inhibitors
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Therapeutic Areas
NeoplasmsRespiratory DiseasesDigestive System Disorders
Active Indication
Advanced Malignant Solid NeoplasmNon-Small Cell Lung CancerLocally Advanced Malignant Solid Neoplasm+ [3]
Inactive Indication-
Originator Organization
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
Active Organization
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Suzhou Suncadia Biopharmaceuticals Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

8
Clinical Trials associated with SHR-9839
NCT07229638
/ RecruitingPhase 1/2
An Open-label, Multicenter Phase IB/II Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors
NCT06915142
/ RecruitingPhase 2
An Phase II Clinical Study on the Safety, Tolerability and Efficacy of HRS-7058 in Combination With Antitumor Drugs in Subjects With Solid Tumors
NCT06754930
/ RecruitingPhase 1/2
A Multicenter, Open Phase IB/II Clinical Study of Safety, Tolerability, and Efficacy of SHR-1826 in Combination With Other Anti-cancer Treatment in Patients With Non-small Cell Lung Cancer
100 Clinical Results associated with SHR-9839
Login to view more data
100 Translational Medicine associated with SHR-9839
Login to view more data
100 Patents (Medical) associated with SHR-9839
Login to view more data
100 Deals associated with SHR-9839
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Suzhou Suncadia Biopharmaceuticals Co., Ltd.
18 Feb 2025
Non-Small Cell Lung CancerPhase 2
China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Suzhou Suncadia Biopharmaceuticals Co., Ltd.
18 Feb 2025
Locally Advanced Malignant Solid NeoplasmPhase 2
China
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
02 Jul 2024
KRAS G12D mutation Colorectal cancerIND Approval
China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Suzhou Suncadia Biopharmaceuticals Co., Ltd.
09 Jan 2026
HER2 Positive Colorectal CancerIND Approval
China
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
16 Dec 2024
KRAS G12D mutation Solid TumorsIND Approval
China
Shanghai Hengrui Pharmaceutical Co., Ltd.Shanghai Hengrui Pharmaceutical Co., Ltd.
02 Apr 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free